Biofrontera Inc. (BFRI)
1.04
-0.09 (-7.96%)
At close: Jan 14, 2025, 3:59 PM
1.01
-3.35%
Pre-market Jan 15, 2025, 07:49 AM EST
Company Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
It also Xepi, a prescription cream for the treatment of impetigo.
The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc.
| Country | United States |
| IPO Date | Oct 29, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 83 |
| CEO | Dr. Hermann Luebbert Ph.D. |
Contact Details
Address: 120 Presidential Way Woburn, Massachusetts United States | |
| Website | https://www.biofrontera.us.com |
Stock Details
| Ticker Symbol | BFRI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001858685 |
| CUSIP Number | 09077D100 |
| ISIN Number | US09077D2099 |
| Employer ID | 47-3765675 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hermann Luebbert Ph.D. | Chief Executive Officer, President & Executive Chairman |
| Eugene Frederick Leffler III | Chief Financial Officer |
| Alycia Torres | Vice President of Administration |
| Daniel Hakansson J.D. | General Counsel & Head of Compliance |
| Erica F. Gates CPA, M.B.A. | Senior Director of Finance & Principal Accounting Officer |
| Jon Lyons M.B.A., Ph.D. | Vice President of Scientific & Medical Affairs |
| Mark Baldyga | Vice President of Sales & Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | SCHEDULE 13D/A | [Amend] Filing |
| Dec 05, 2024 | D | Filing |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | S-8 | Filing |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |